Bioxytran, Inc. (OTCMKTS:BIXT) Sees Significant Decline in Short Interest

Bioxytran, Inc. (OTCMKTS:BIXT) was the target of a significant decrease in short interest in the month of March. As of March 13th, there was short interest totaling 300 shares, a decrease of 97.1% from the February 26th total of 10,300 shares. Based on an average trading volume of 1,769,827 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.0% of the company’s stock are sold short. Currently, 0.0% of the company’s stock are sold short. Based on an average trading volume of 1,769,827 shares, the days-to-cover ratio is currently 0.0 days.

Bioxytran Trading Up 14.6%

Shares of OTCMKTS BIXT opened at $0.05 on Wednesday. The stock has a market cap of $5.51 million, a P/E ratio of -1.62 and a beta of 2.14. The business’s fifty day simple moving average is $0.05 and its 200-day simple moving average is $0.06. Bioxytran has a 12-month low of $0.03 and a 12-month high of $0.23.

Bioxytran Company Profile

Bioxytran, Inc is a clinical-stage biotechnology company focused on the development of synthetic oxygen carriers and novel oxygen therapeutics for acute care and chronic disease applications. The company’s proprietary platform is designed to safely deliver therapeutic levels of oxygen to hypoxic tissues, addressing conditions such as ischemia-reperfusion injury, organ transplantation, and traumatic injury. Its lead product candidates target unmet medical needs in cardiovascular and neurological disorders, wound healing, and critical care settings.

Bioxytran’s research pipeline comprises multiple preclinical-stage assets that leverage stabilized perfluorocarbon emulsions to achieve controlled oxygen release.